EU: Hansa Idefirix Achieves 90% One-Year Graft Survival in Kidney Transplantation
Hansa Biopharma has announced positive top-line results from a post-approval efficacy study of Idefi...
Australia's Noxopharm Unveils TLR8 Enhancement Method, Boosting Activity by Over 200-Fold
Olivier Laczka, CEO of Australian biotechnology company Noxopharm Limited, introduced new advances i...
Ractigen Therapeutics' saRNA Reduces Fat by 45%, Accepted for ADA 2026 Poster Presentation
Ractigen Therapeutics announced that the latest research abstract on its first-in-class small activa...
Antengene Presents ATG-207 Immune Tolerance Data at EULAR
Antengene Corporation Limited (HKEX: 6996.HK) presented preclinical data for ATG-207, an alpha-maske...
Korea Dayspring Pharma Announces Positive Phase II Clinical Results for CG2001 in Treating Androgenetic Alopecia
Dayspring Pharma announced positive top-line results from its Phase II clinical trial of the candida...
China's OriCell GPC3 CAR-T Approved for Phase II Liver Cancer Trial
OriCell Therapeutics Holdings Limited ("OriCell") announced that its self-developed autologous CAR-T...
DBV Technologies to Participate in Goldman Sachs Healthcare Conference
DBV Technologies announced that Chief Executive Officer Daniel Tassé will participate in a fireside ...
Cullinan to Present CLN-978 Clinical Data at EULAR
Cullinan Therapeutics (Nasdaq: CGEM) announced that it will present preliminary clinical data from t...
MannKind Showcases New Afrezza Pediatric Data at ADA
MannKind Corporation will present new clinical and real-world data on its products Afrezza (human in...
Denmark's Antag Presents Positive Phase 1 Results for AT7687 at ADA Annual Meeting
Antag Therapeutics presented Phase 1 and preclinical data for its GIP receptor antagonist AT7687 at ...